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This study evaluated the action of tamoxifen and estradiol on the
function of isolated liver mitochondria. We observed that although
tamoxifen and estradiol per se did not affect mitochondrial com-
plexes II, III, or IV, complex I is affected, this effect being more
drastic (except for state 4 of respiration) when mitochondria were
coincubated with both drugs. Furthermore, using two respiratory
chain inhibitors, rotenone and diphenyliodonium chloride, we
identified the flavin mononucleotide site of complex I as the target
of tamoxifen and/or estradiol action(s). Tamoxifen (25 M) per se
induced a significant increase in hydrogen peroxide production and
state 4 of respiration. Additionally, a significant decrease in respi-
ratory control ratio, transmembrane, and depolarization potentials
were observed. Estradiol per se decreased carbonyl cyanide p-triflu-
oromethoxyphenylhydrazone (FCCP)-stimulated respiration, state
3 of respiration, and respiratory control ratio and increased lag
phase of repolarization.With the exception of state 4 of respiration
whose increase induced by tamoxifen was reversed by the presence
of estradiol, the effects of tamoxifen were highly exacerbated when
estradiol was present. We observed that 10 M tamoxifen in the
presence of estradiol affected mitochondria significantly by
decreasing FCCP-stimulated respiration, state 3 of respiration, res-
piratory control ratio, and ADP depolarization and increasing the
lag phase of repolarization. All of the deleterious effects induced by
25 M tamoxifen were highly exacerbated in the presence of estra-
diol. Furthermore, we observed that the effects of both compounds
were independent of estrogen receptors because the pure estrogen
antagonist ICI 182,780 did not interfere with tamoxifen and/or
estradiol detrimental effects. Altogether, our data provide a mech-
anistic explanation for the multiple cytotoxic effects of tamoxifen
including its capacity to destroy tamoxifen-resistant breast cancer
cells in the presence of estradiol. This new piece of information
provides a basis for the development of new and promising anti-
cancer therapeutic strategies.
Selective estrogen receptormodulators, also known as tissue selective
estrogens, are a class of drugs with mixed estrogen agonist/antagonist
actions (1). They were originally classified as antiestrogens because of
their ability to antagonize the proliferative effects of estrogens (2). It was
later discovered that these compounds could antagonize the action of
estrogen by binding to the estrogen receptor (ER)2 to thereby block
estradiol (E2) access (1, 3). It is now known that under certain circum-
stances and in certain tissues, in addition to acting as competitive inhib-
itors of endogenous estrogen, these same estrogen antagonists can exert
estrogenic agonist properties (4–6). These findings indicate that the
mechanisms regulating ER function are not the same in all cells and that
a compound can only be classified as an ER agonist or antagonist in
relation to a specific cell type or process.
It is known for a long time that breast cancer is an estrogen-depend-
entmalignancy. Based on this finding, the current strategy for treatment
of hormone-dependent breast cancer is to block the action of estrogen
on cancer cells either by inhibiting estrogen frombinding to ER using an
antiestrogen (7) or preventing its synthesis using an aromatase inhibitor
(8). Tamoxifen (TAM), the first clinically useful selective estrogen
receptor modulators (9), has antiestrogenic effects in the breast tissue
and is the standard endocrine treatment for postmenopausal women
with breast cancer. Currently, the standard of care for breast cancer is 5
years of TAM (7) or an aromatase inhibitor such as anastrazole (8).
However, the consequence of long termTAMtherapy is drug resistance
(10, 11). Although, resistance to TAM has been well documented (10,
12, 13), evidence suggests the emergence of a new form of drug resist-
ance that develops after many years of selective estrogen receptor mod-
ulator therapy (14). A recent study showed that TAM-resistant breast
cancer can be reversed by the use of low doses of E2 for a short period of
time to resensitize ER-positive tumors again to the growth inhibitory
effects of antiestrogens (15). However, and as far as we know, this effect
was not explored in a mechanistic point of view. We chose mitochon-
dria as an experimental model because it is increasingly recognized that
these organelles are essential for generating energy that fuels normal
cellular function and, at the same time, are the major intracellular
source of cytotoxic free radicals and the primary determinants of cell
death (16). The unique role of the mitochondria is in supplying high
energy ATP molecules, while at the same time, monitoring cellular
health to make a rapid decision to initiate a programmed cell death. As
such, mitochondria sit at a strategic position in the hierarchy of cellular
organelles to continue the healthy life of the cell or to terminate it.
Furthermore, accumulating evidence indicates that both E2 (17, 18) and
TAM (19–22) are capable of modulating mitochondrial function. To
achieve our goal, we evaluated several mitochondrial parameters from
the respiratory chain (states 3 and 4 of respiration, respiratory control
ratio (RCR), ADP/O ratio, and FCCP-stimulated respiration), oxidative
phosphorylation system (transmembrane, depolarization, and repolar-
ization potentials and lag phase of repolarization), and the capacity of* The costs of publication of this article were defrayed in part by the payment of page
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mitochondria to produce hydrogen peroxide. Furthermore, to identify
the specific site(s) of TAM and/or E2 action(s), we performed our
experiments in the presence/absence of two respiratory chain inhibi-
tors, rotenone and diphenyliodonium chloride (DPI), and the pure
estrogen antagonist ICI 182,780.
EXPERIMENTAL PROCEDURES
Materials—TAM and E2 were obtained from Sigma. DPI was
obtained from Aldrich, and ICI 182,780 was obtained from TOCRIS
(UK). All of the other chemicals were of the highest grade of purity
commercially available.
Animals—Male Wistar rats (3 months old) were housed in our ani-
mal colony (Laboratory ResearchCenter, UniversityHospital, Coimbra,
Portugal). They were maintained under controlled light (12 h day/night
cycle) and humidity with free access (except in the fasting period) to
water and powdered rodent chow (URF1; Charles River). Adhering to
procedures approved by the Institutional Animal Care and Use Com-
mittee, the animals were sacrificed by cervical displacement and
decapitation.
Isolation of Liver Mitochondria—The animals were killed by cervical
displacement, and the mitochondria were isolated by conventional
methods (23) with slight modifications. Briefly, the liver mitochondria
were isolated in a medium containing 250mM sucrose, 5 mMHepes, 0.5
mM EGTA, and 0.1% defatted bovine serum albumin (pH 7.2). EGTA
and bovine serum albumin were omitted from the final washing
medium. The mitochondrial pellet was washed twice and suspended in
the washing medium. Mitochondrial protein was determined by the
biuret method calibrated with bovine serum albumin (24).
Mitochondrial Respiration—Oxygen consumption of isolated mito-
chondria was monitored polarographically with a Clark oxygen elec-
trode (25) connected to a suitable recorder in a 1-ml thermostatted
water-jacketed closed chamber with magnetic stirring. The reactions
were carried out at 30 °C in 1 ml of the standard medium with 1 mg of
protein. ICI (1 min) and/or E2 (1 min) and/or TAM (2 min) were incu-
bated with isolates before 5 mM glutamate/2.5 mM malate or 5 mM
succinate addition.
Membrane Potential (m) Measurements—The mitochondrial
transmembrane potential (m) was monitored by evaluating trans-
membrane distribution of the lipophilic cation tetraphenylphospho-
nium (TPP) with a TPP-selective electrode prepared according to
Kamo et al. (26) using a Ag/AgCl-saturated electrode (Tacussel, model
MI 402) as reference. TPP uptake has been measured from the
decreased TPP concentration in the medium sensed by the electrode.
The potential difference between the selective electrode and the refer-
ence electrode was measured with an electrometer and recorded con-
tinuously in a Linear 1200 recorder. The voltage response of the TPP
electrode to log[TPP] was linear with a slope of 59  1, in a good
agreement with the Nernst equation. The reactions were carried out in
a chamber with magnetic stirring in 1 ml of the standard medium (130
mM sucrose, 50 mM KCl, 2.5 mM MgCl2, 2.5 mM KH2PO4, 100 M
EGTA, 5 mM Hepes, pH 7.4) containing 3 M TPP. This TPP con-
centration was chosen to achieve high sensitivity in measurements and
to avoid possible toxic effects on mitochondria (27, 28). The m was
estimated by the following equation as indicated by Kamo et al. (26) and
Muratsugu et al. (29).
m (mV) 59 log(v/V ) 59 log(10
E/59 1) (Eq. 1)
v, V, and E stand for mitochondrial volume, volume of the incubation
medium, and deflection of the electrode potential from the base line,
respectively. This equation was derived assuming that TPP distribu-
tion between the mitochondria and the medium follows the Nernst
equation and that the law of mass conservation is applicable. A matrix
volume of 1.1 l/mg protein was assumed. No correction was made for
the “passive” binding contribution of TPP to the mitochondrial mem-
branes because the purpose of the experiments was to show relative
changes in potentials rather than absolute values. As a consequence, we
can anticipate a slight overestimation on m values. However, the
overestimation is only significant at m values below 90 mV, there-
fore, far from our measurements. Neither TAM nor E2 affected TPP
binding to mitochondrial membranes on the electrode response.
Mitochondria (1 mg/ml) were energized by the addition of 5 mM
glutamate/2.5 mMmalate. After a steady state distribution of TPP had
been reached (1 min of recording), ICI and/or E2 and/or TAM were
added, and m fluctuations were recorded.
Evaluation of Hydrogen Peroxide Production—The rate of H2O2 pro-
duction was measured fluorimetrically using a modification of the
method described by Barja (30). Briefly, the mitochondria were incu-
bated at 30 °C with 5 mM glutamate/2.5 mM malate in 1.5 ml of phos-
phate buffer (pH 7.4) containing 0.1 mM EGTA, 5 mM KH2PO4, 3 mM
MgCl2, 145 mM KCl, 30 mM Hepes, 0.1 mM homovalinic acid, and 6
units/ml horseradish peroxidase in the presence or absence of 1mM ICI,
FIGURE 1. Representative traces of the effect of TAMand/or E2 on FCCP-stimulated
respiration. Freshly isolated liver mitochondria (1 mg) in 1 ml of the standard medium
were energized with 5 mM glutamate/2.5 mM malate (A) or 5 mM succinate (B). The iso-
lates were incubated with TAM and E2 for 2 and 1 min, respectively, at 30 °C, before
mitochondria energization. The values of TAM and E2 are in M.
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0.5mMDPI, rotenone and E2 and/or TAM.The incubationwas stopped
at 15minwith 0.5ml of cold 2 M glycine buffer containing 25mMEDTA
and NaOH (pH 12). The fluorescence of supernatants was measured at
312-nm excitation wavelength and 420-nm emission wavelength. The
rate of H2O2 was calculated using a standard curve of H2O2.
Statistical Analysis—The results are presented as themeans S.E. of
the indicated number of experiments. Statistical significance was deter-
mined using the one-way analysis of variance test for multiple compar-
isons, followed by the post hoc Tukey-Kramer test.
RESULTS
Mitochondrial Complex I Is the Key Target of the Deleterious Effects
Induced by E2 Plus TAM—In control conditions after the addition of
glutamate/malate (substrate of complex I) there was a slight increase in
oxygen consumption (state 2 of respiration) caused by the activation of
the mitochondrial respiratory chain (Fig. 1A). The addition of 1 M
FCCP, a well known respiratory chain uncoupler, promoted a signifi-
cant stimulation of oxygen consumption (Figs. 1A and 2). The preincu-
bation of mitochondria with 25 M E2, 10 M, and 25 M TAM signif-
icantly decreased the consumption of oxygen induced by 1 M FCCP
(37, 20, and 19%, respectively) when comparedwith control condition
(Fig. 2). However, the coincubation of mitochondria with 25 M E2 and
TAM (10 or 25 M) exacerbated the decrease in FCCP-induced oxygen
consumption,with this effect beingmuchmore pronounced in the pres-
ence of the highest concentration of TAM (52 and 79%, respectively)
when compared with control condition (Figs. 1A and 2). The preincu-
bation of mitochondria with 30 M E2 and 25 M TAM completely
abolished FCCP-stimulated respiration (Fig. 1A). In contrast, when
these conditions were tested in mitochondrial complex II (using succi-
nate as substrate), we did not observe any statistical difference when we
compared mitochondria without treatment with those incubated with
E2 and/or TAM (Fig. 1B). These results indicate that mitochondrial
complex I is the target of E2 and TAM.
Respiratory Chain Activity Is Drastically Affected When Mitochon-
dria Are Coincubated with E2 and TAM—RCR is the ratio between
mitochondrial respiration states 3 (consumption of oxygen in the pres-
FIGURE 2. Effect of TAM and/or E2 on FCCP-stimulated respiration. Freshly isolated
liver mitochondria (1 mg) in 1 ml of the standard medium were energized with 5 mM
glutamate/2.5mMmalate. The isolates were incubatedwith TAM and E2 for 2 and 1min,
respectively, at 30 °C, before mitochondria energization. aaa, p  0.001; a, p  0.05,
when compared with FCCP-stimulated respiration. bbb, p  0.001; b, p  0.05, when
comparedwithFCCP-stimulatedrespiration inthepresenceof25ME2.ccc,p0.001,when
compared with FCCP-stimulated respiration in the presence of 10 M TAM. ddd, p 0.001,
when compared with FCCP-stimulated respiration in the presence of 25 M TAM. eee, p
0.001,when comparedwith FCCP-stimulated respiration in thepresenceof 25ME2and10
M TAM. The data shown represent themeans S.E. from six independent experiments.
FIGURE 3. Effect of TAMand/or E2 on state 4 of respiration (consumption of oxygen
after ADP phosphorylation). Freshly isolated liver mitochondria (1 mg) in 1 ml of the
standardmediumwereenergizedwith5mMglutamate/2.5mMmalate. The isolateswere
incubated with TAM and E2 for 2 and 1 min, respectively, at 30 °C, before mitochondria
energization.aaa,p0.001;a,p0.05whencomparedwith control condition.bbb,p
0.001; b, p  0.05, when compared with 25 M E2. ccc, p  0.001; e, p  0.05 when
compared with 30 M E2. dd, p 0.01, when compared with 10 M TAM. eee, p 0.001;
ee, p 0.01; e, p 0.05, when compared with 25 M TAM. jj, p 0.01; j, p 0.05, when
comparedwith ICI condition. kk,p0.01; k,p0.05,whencomparedwith ICI plus 25M
E2. The data shown represent the means S.E. from six independent experiments.
FIGURE 4. Effect of TAMand/or E2 on state 3 of respiration (consumption of oxygen
in the presence of substrate and ADP). Freshly isolated liver mitochondria (1 mg) in 1
ml of the standard medium were energized with 5 mM glutamate/2.5 mM malate. The
isolates were incubated with TAM and E2 for 2 and 1 min, respectively, at 30 °C, before
mitochondria energization.aaa,p0.001;aa,p0.01;a,p0.05,whencomparedwith
control condition. c, p 0.05, when comparedwith 30M E2. ddd, p 0.001; d, p 0.05
when comparedwith 10M TAM. eee, p 0.001; e, p 0.05, when comparedwith 25M
TAM. The data shown represent the means S.E. from six independent experiments.
Tamoxifen and Estradiol Inhibit Mitochondrial Complex I
APRIL 14, 2006•VOLUME 281•NUMBER 15 JOURNAL OF BIOLOGICAL CHEMISTRY 10145












ence of substrate and ADP) and 4 (consumption of oxygen after ADP
has been consumed). We observed that 25 M TAM induced a signifi-
cant increase in respiration state 4 (143%) when compared with con-
trol condition (Fig. 3). However, coincubation of E2 with TAM
decreased this parameter to a value similar to that of control conditions
(Fig. 3). Preincubation of mitochondria with ICI, the pure estrogen
antagonist, did not affect this parameter, indicating that estrogen recep-
tors arenot involved in these effects.This finding is supportedby the results
obtainedwithmitochondria incubatedwith ICI andTAM(25M) aloneor
in combination with E2 (25 M) because the increase observed in respira-
tion state 4 (101 and 90%, respectively) is not statistically significant
compared with that induced by 25 M TAM per se (Fig. 3).
When we analyzed respiration state 3, we observed that 30 M E2
induced a decrease of this parameter (34%) when compared with con-
trol condition (Fig. 4). Similarly, coincubation of mitochondria with E2
(25 or 30 M) and 10 MTAM induced a decrease in respiration state 3
(36 and 35%, respectively), and this effect was exacerbated when both
E2 concentrations were present with 25 M TAM (47 and 53%,
respectively) (Fig. 4). ICI in the presence of E2 (25 M) alone or in
combination with TAM (25 M) induced a significant decrease in res-
piration state 3 (38 and 52%, respectively) when compared with con-
trol condition (Fig. 4). However, this decrease was not statistically sig-
nificant from that induced by 25 M E2, indicating that the effect on
respiration state 3 is only due to E2 action (Fig. 4).
Fig. 5 shows that 25 and 30 M E2 induced a similar decrease in RCR
(26 and 36%) and that 25MTAMpromoted a drastic decrease of this
parameter (64%) when compared with control condition. However,
coincubation of mitochondria with 25 or 30 M E2 and 10 M TAM
significantly potentiated the decrease in RCR (51 and 58%, respec-
tively), and this potentiation was more pronounced when both concen-
trations of estradiol were present with 25 M TAM (72 and 76%,
respectively), when compared with control condition. Once again, ICI
per se did not affect RCR (Fig. 5).
The ADP/O ratio, an indicator of oxidative phosphorylation effi-
ciency, is expressed by the ratio between the amount of ADP added and
the oxygen consumed during state 3 respiration.Weobserved that coin-
cubation of 25 or 30ME2with 25MTAM induced a similar decrease
in the ADP/O ratio (37% and 21%, respectively) when compared
with control condition (Fig. 6). Similar to what happened with the pre-
vious parameters analyzed, ICI did not interfere with ADP/O ratio (Fig.
6). Although we observed a decrease in ADP/O ratio when mitochon-
dria were coincubated with ICI, 25 M E2, and 25 M TAM, this effect
was not statistically different from that induced by E2 and TAM in the
absence of ICI (Fig. 6).
Oxidative Phosphorylation System Is Drastically AffectedWhenMito-
chondria Are Coincubated with E2 and TAM—The mitochondrial
transmembrane potential (m) is fundamental for the phenomenonof
oxidative phosphorylation, the conversion of ADP to ATP via ATP syn-
thase. Mitochondrial respiratory chain pumps H out of themitochon-
drial matrix across the inner mitochondrial membrane. The H gradi-
ent forms an electrochemical potential (p), resulting in a pH (pH)
and a voltage gradient (m) across the mitochondrial inner mem-
brane. m developed by mitochondria after energization with gluta-
mate/malate was 220 mV (negative inside) (Fig. 7). However, the
addition of TAMaftermitochondria energization induced a decrease in
m, as shown in Figs. 7 and 8. Because the addition of E2 (25 or 30M)
did not significantly affectm, we compared the alterations promoted
by the other conditions on m with that induced by E2. We observed
that, with the exception of 10 M TAM, all of the other experimental
conditions induced a significant decrease inm , with this effect being
much more pronounced when 25 M TAM was present with 25 and
FIGURE 5. Effect of TAM and/or E2 on RCR (ratio between states 3 and 4 of respira-
tion). Freshly isolated liver mitochondria (1 mg) in 1 ml of the standard medium were
energized with 5 mM glutamate/2.5 mM malate. The isolates were incubated with TAM
and E2 for 2 and 1min, respectively, at 30 °C, beforemitochondria energization. aaa, p
0.001; a, p 0.05, when compared with control condition. bbb, p 0.001; b, p 0.05,
when compared with 25M E2. c, p 0.05, when compared with 30M E2. dd, p 0.01;
d, p 0.05; when comparedwith 10M TAM. eee, p 0.001, when comparedwith 25M
TAM. f, p 0.05 when compared with 25 M E2 plus 10 M TAM. ggg, p 0.001; g, p
0.05, when comparedwith 25M E2 plus 25M TAM. hh, p 0.01, when comparedwith
30 M E2 plus 10 M TAM. iii, p 0.001; ii, p 0.01, when compared with 30 M E2 plus
25 M TAM. jjj, p 0.001, when compared with ICI conditions. kk, p 0.01, when com-
pared with ICI plus 25 M E2. The data shown represent the means  S.E. from six
independent experiments.
FIGURE 6. Effect of TAM and/or E2 on ADP/O (the ratio between the amount of ADP
added and the oxygen consumedduring the state 3 of respiration). Freshly isolated
liver mitochondria (1 mg) in 1 ml of the standard medium were energized with 5 mM
glutamate/2.5mMmalate. The isolates were incubatedwith TAM and E2 for 2 and 1min,
respectively, at 30 °C, before mitochondria energization. aaa, p  0.001; aa, p  0.01,
when comparedwith control condition. cc,p0.01,when comparedwith 30ME2.ggg,
p 0.001,when comparedwith 25M E2plus 25MTAM. Thedata shown represent the
means S.E. from six independent experiments.
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30 M E2 (77 and 101%, respectively) when compared with E2 alone
(Fig. 7).
Although the depolarization induced by ADP was not statistically
affected when we compared E2 and/or TAM effects with control con-
dition, we observed that the repolarization potential (capacity of mito-
chondria to reestablish m, after ADP phosphorylation) decreased
similarly in the presence of 25 M TAM (5%), 25 M E2 plus 10 M
TAM (5%), 25 M E2 plus 25 M TAM (8%), and 30 M E2 plus 10
MTAM(8%)when comparedwith control conditions (Figs. 7 and 9).
It should be noted that the presence of 30 M E2 plus 25 M TAM
potentiated the decrease of repolarization potential (11%) when com-
pared with control condition (Fig. 9). It is noteworthy that ICI did not
interfere with this parameter (Fig. 9).
The lag phase of repolarization (time necessary for ADP phospho-
rylation) was significantly affected by 25 and 30M E2 (58 and 69%,
respectively) when compared with control condition (Figs. 7 and 10).
This effect of E2 was exacerbated in the presence of 10 M TAM
(66 and 92%, respectively) and 25MTAM (97 and 159%, respec-
tively) (Figs. 7 and 10). Additionally, the presence of ICI did not
induce any statistical difference in the lag phase of repolarization
(Fig. 10).
Hydrogen Peroxide Production Is Potentiated When Mitochondria
Are Coincubated with E2 andTAM: FMN Is the Site in Complex IWhere
Both Compounds Exert Their Effects—The production ofH2O2 bymito-
chondria gives an indication about the propensity of mitochondria to
originate and/or exacerbate oxidative stress. At basal conditions (con-
FIGURE 7. Representative traces of the effect of TAM and/or E2 on m. Freshly isolated liver mitochondria (1 mg) in 1 ml of the standard medium were energized with 5 mM
glutamate/2.5 mM malate. After a steady state distribution of TPP had been reached (1 min of recording), TAM and/or E2 were added to mitochondrial suspension.
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trol), we observed that incubation of mitochondria with 25 M TAM
induced an increase on H2O2 production (41%) (Table 1). However,
after the coincubation of mitochondria with 30 M E2 and 25 M
TAM/mg protein, we observed a potentiation in H2O2 production
(84%) when comparedwith untreatedmitochondria (Table 1). Except
in the conditions where 25 M TAM was present, rotenone pretreat-
ment increased the levels of H2O2 in all of the conditions tested when
compared with levels generated by mitochondria not exposed to com-
plex I inhibitors (Table 1). In the presence of ICI, we observed that
incubation ofmitochondriawith25MTAMinducedan increase inH2O2
production (32%) (Table 1), this effect being exacerbated when mito-
chondria were coincubated with 30ME2 and 25MTAM (88%) when
compared with the untreated mitochondria (Table 1). In the presence of
DPI, which irreversibly binds to the FMN site in complex I, we did not
observe any statistical difference between the several experimental condi-
tions assayed, and in all cases, the level of H2O2 production was very low
(Table 1), indicating that both TAM and E2 exert their effects on H2O2
production through the FMN site of complex I.
DISCUSSION
Here we show that TAM and/or E2 act(s) directly on the FMN site of
complex I leading to mitochondrial failure. These results also provide a
mechanistic basis to explain how E2 treatment is capable of reversing
TAM-induced resistant cancers. Resistance to TAM involves changes
that prevent apoptosis and enhance cell proliferation and survival.
Recently, Osipo et al. (15) observed that with long term therapy (5
years), a distinct phase of resistance develops where TAM stimulates
growth of breast cancer but in the presence of E2 apoptosis is induced,
inhibiting tumor growth. Furthermore, we also demonstrate that mito-
chondrial failure induced by TAM and/or E2 is independent of ER.
Changes in the structural and functional characteristics ofmitochon-
dria provide a number of primary targets for drug-induced toxicity and
cell death (31). Previously, we have reported that TAM-induced alter-
ations of mitochondrial bioenergetic capacity may be involved in its
antiproliferative ER-independent activity and side effects on different
cell types (32). It was shown that when mitochondria were energized
FIGURE 8. Effect of TAM and/or E2 onm. Freshly isolated liver mitochondria (1 mg)
in 1 ml of the standard medium were energized with 5 mM glutamate/2.5 mM malate.
After a steady state distribution of TPP had been reached (1 min of recording), TAM
and/or E2 were added to mitochondrial suspension. aaa, p 0.001; aa, p 0.01; a, p
0.05, when compared with estradiol. bbb, p  0.001; bb, p  0.01; b, p  0.05, when
compared with 10M TAM. ccc, p 0.001; c, p 0.05, when compared with 25M TAM.
eee, p 0.001; ee, p 0.01, when compared with 25 M TAM plus 25 M E2. f, p 0.05
when comparedwith 30M E2 plus 10M TAM. g, p 0.05, when comparedwith 25M
E2 plus 25 M TAM. The data shown represent the means  S.E. from six independent
experiments.
FIGURE 9. Effect of TAM and/or E2 on repolarization potential
(capacity of mitochondria to reestablishm after ADP phos-
phorylation). Freshly isolated liver mitochondria (1 mg) in 1 ml of
the standardmediumwere energizedwith 5mMglutamate/2.5mM
malate. After a steady state distribution of TPP had been reached
(1 min of recording), TAM and/or E2 and/or ICI were added to
mitochondrial suspension. aaa, p 0.001; aa, p 0.01, when com-
pared with control condition. bbb, p  0.001; bb, p  0.01, when
comparedwith25ME2. ccc,p0.001; c,p0.05,whencompared
with 30M E2. ddd, p 0.001; d, p 0.05, when compared with 10
M TAM. ee, p 0.01, when compared with 25 M TAM. f, p 0.05
when compared with 25 M E2 plus 10 M TAM. g, p 0.05, when
compared with 25 M E2 plus 25 M TAM. h, p 0.05, when com-
paredwith 30M E2 plus 10M TAM. iii, p 0.001; i, p 0.05, when
compared with 30M E2 plus 25M TAM. jjj, p 0.001, when com-
pared with ICI conditions. kkk, p 0.001, when compared with ICI
plus 25M E2. The data shown represent themeans S.E. from six
independent experiments.
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with succinate only high TAM concentrations (above 40 nmol/mg pro-
tein) stimulate the rate of state 4 respiration, inhibit state 3, and uncou-
ple the mitochondrial respiration (32). Similarly, Tuquet et al. (33)
observed that increasing concentrations of TAM (30–90 M) act as
both an uncoupling agent and a powerful inhibitor of electron transport
in liver mitochondria. In agreement with those findings, we now
observed that respiration of mitochondria energized with succinate is
not affected by lower TAM concentrations (10 and 25 M) (Fig. 1B). In
marked contrast, 25 M TAM significantly affects mitochondrial com-
plex I. This effect may explain the process of cell death induced by this
anticancer agent in different cell types, including ER-negative breast
cancer (34), lung adenocarcinoma (35), prostate cancer (36), ovarian
carcinoma (37), virus (38), and bacteria (39) because functional mito-
chondria are needed for cell survival. Accordingly, we observed that 25
M TAM induces a significant increase in state 4 of respiration (Fig. 3)
and H2O2 production (Table 1) and a significant decrease in RCR (Fig.
5), m (Figs. 7 and 8) and depolarization potential (Fig. 9). Mitochon-
drial dysfunction induced by TAM may be an important early event in
the activation of apoptosis, a critical process for the destruction of
malignant cells. Recently, Gauduchon et al. (40) reported that
hydroxytamoxifen, an active metabolite of TAM, at pharmacological
concentrations inhibits cell proliferation; this inhibition is achieved by
two independent events: a block at the G1 phase of the cell cycle and the
induction of apoptotic death through the activation of an intrinsicmito-
chondrial caspase-9-dependent pathway.
TAM usually is administered at a daily dose of 20 mg/kg of body
weight, and the range of TAM serum levels is between 50 and 300 ng/ml
(0.8 M) (34). However, steady state tissue concentrations of TAM in
rats and humans, including the hepatic tissue, are 60–70 times higher
than in serum (41), because of its strong partitioning in biomembranes
(42), and at least 4 weeks of administration are required to reach steady
state drug concentrations (34). Therefore, the estimated drug concen-
trations in peripheral tissues may reach values (10–50 M) in the
range of our study.
This study also shows that E2 decreases FCCP-stimulated respiration
(Figs. 1A and 2), state 3 respiration (Fig. 4), and RCR (Fig. 5) and
increases lag phase of repolarization (Fig. 10). Natural estrogens, 17-
estradiol, E2, and estrone, at micromolar concentrations were demon-
strated to inhibit mitochondrial electron transport in homogenates of
rat uterus, liver, and skeletal muscle (43). Furthermore, Hagen et al. (44)
reported that 2-methoxyestradiol, a naturally occurring metabolite of
E2, inhibits mitochondrial respiration in both intact cells and submito-
chondrial particles and that this effect is due to inhibition of complex I
FIGURE 10. Effect of TAM and/or E2 on lag phase
of repolarization (time necessary for ADP phos-
phorylation). Freshly isolated liver mitochondria
(1 mg) in 1 ml of the standard medium were ener-
gized with 5 mM glutamate/2.5 mM malate. After a
steady state distributionof TPPhadbeen reached
(1 min of recording), TAM and/or E2 and/or ICI
were added tomitochondrial suspension. aaa, p
0.001; aa, p  0.01; a, p  0.05, when compared
with control condition. bbb, p 0.001; bb, p 0.01,
when compared with 25 M E2. ccc, p  0.001; c,
p 0.05, when compared with 30 M E2. ddd, p
0.001; dd, p  0.01; when compared with 10 M
TAM. eee, p 0.001; ee, p 0.01, when compared
with 25 M TAM. fff, p  0.001; f, p  0.05 when
compared with 25 M E2 plus 10 M TAM. gg, p
0.01, when compared with 25 M E2 plus 25 M
TAM. iii, p 0.001, when compared with 30 M E2
plus 25MTAM. jjj,p 0.001,when comparedwith
ICI conditions. kkk, p 0.001, when comparedwith
ICI plus 25 M E2. The data shown represent the
means S.E. from six independent experiments.
TABLE 1
Effect of TAM and/or E2 on H2O2 production
Freshly isolated liver mitochondria were incubated at 0.2 mg protein/ml under
standard conditions as described under “Experimental Procedures.” The values of
H2O2 are given in nmol/mg protein/15min. The data shown represent themeans
S.E. from six independent experiments. ND, not determined.
Control Rotenone ICI DPI
Untreated 2.66 0.13 3.26 0.28 2.00 0.31 0.81 0.06
10 M E2 2.59 0.14 3.40 0.24 2.02 0.24 0.70 0.02
30 M E2 2.17 0.26 2.68 0.41 1.62 0.28 0.68 0.07
10 M TAM 2.12 0.12 2.73 0.24 1.56 0.16 0.76 0.03
25 M TAM 3.74 0.63a 3.45 0.13 2.64 0.55a 0.99 0.14
10 E2 10 TAM 2.39 0.26 2.28 0.30 2.43 0.41 0.75 0.08
30 E2 25 TAM 4.88 0.84b 4.69 0.91b 3.75 0.89b 1.06 0.22
Catalase 2.80 0.40 2.71 0.29 ND ND
ap 0.05 when compared with the untreated condition.
b p 0.01 when compared with the untreated condition.
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of the mitochondrial electron transport chain. Recently, Mishra and
Shaha (45) reported that estrogen-induced spermatogenic cell apopto-
sis occurs via the mitochondrial pathway.
Although estrogen synthesis occurs in the mitochondria, exog-
enously added estrogen is also transported to this organelle. For
instance, in vivo exposure of ovariectomized rats to tritiated E2 showed
with increasing time the translocation of this hormone from the plas-
malemma mainly to the mitochondria (75%) rather than the nuclei in
liver, adrenal gland, and spleen tissues (46). The lipophilic property of
E2 allows thismolecule to easily diffuse into lipid bilayers. Becausemito-
chondria are enriched with lipids, the organelle has the ability to act as
an estrogen sink within cells.
However, themost interesting aspect of this study is that the effects of
TAM and E2 are highly exacerbated when both compounds are present
simultaneously. Even the lower concentration of TAM tested (10 M),
which alone does not interfere withmitochondrial function, in the pres-
ence of E2 significantly affectsmitochondrial function, exacerbating the
decrease in FCCP-stimulated respiration (Figs. 1A and 2), decreasing
state 3 of respiration (Fig. 4), RCR (Fig. 5) and depolarization potential
(Fig. 9) and increasing the lag phase of repolarization (Fig. 10). Further-
more, all deleterious effects induced by 25 M TAM alone are highly
exacerbated in the presence of E2. These results are in accordance with
a previous study showing that the apoptotic cell death induced by TAM
in GT1–7 cells is stimulated by estrogen treatment (47). Furthermore,
our observations indicate a potential mechanism by which E2 is capable
of reversing the TAM-induced resistance reported in the literature (15),
as previously discussed.
The inhibition of respiratory complex I is known to favor ROS
FIGURE 11. The FMN site of complex I is the target of TAM and/or E2 action. The crosses represent inhibition of electron (e) transfer from the iron/sulfur (Fe/S) center N-2 to
ubiquinone (CoQ) by rotenone and inhibition of e transfer from the FMN to the iron/sulfur centers N-1, N-3, and N-4 by DPI, TAM, and E2. Cyt. c represents cytochrome c.
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generation (Fig. 11). Rat brain mitochondria that respire on complex
I substrates produced a substantial level of ROS when inhibited with
rotenone concentrations as low as 20 nM (48). Complex I inhibitors
rotenone, piericidin A, and amytal have been used in cotreatment
with estrogens to elucidate the site of estrogen action on electron
transfer (43). In MCF7 cells, it was demonstrated that cotreatment
with rotenone and E2 strongly inhibited ornithine decarboxylase
activity by 86% (49). More recently, a study reported that treatment
with 10 M of 2-methoxyestradiol induced apoptosis in Ewing sar-
coma cells through H2O2 production (50). Similarly, we observed
that although at basal conditions E2 does not interfere with H2O2
production, in the presence of rotenone the production of H2O2 is
increased (Table 1). Rotenone blocks the transfer of electrons from
the iron-sulfur center N-2 to ubiquinone (51), which inhibits the
flow of electrons into the ubiquinone-cytochrome bc1 complex;
however, reduction of molecular oxygen to superoxide anion can still
occur at the FMN site of complex I. In contrast, DPI is a potent
arylating agent that reacts with flavoenzymes to form phenylate fla-
vin adducts (52). Hence, DPI irreversibly binds with the FMN in
complex I and inhibits NADH dehydrogenase activity (53). Mito-
chondrial NADH dehydrogenase complex is one site in which super-
oxide anions may be produced during the reoxidation of the FMN.
(Fig. 11). The involvement of FMN site in TAM and/or E2-elicited
ROS production was investigated using rotenone and DPI, which are
both complex I inhibitors but block electron flow at different sites
within the NADH dehydrogenase complex. Our data indicate that
mitochondria incubated with DPI produce low levels of H2O2 (Table
1), indicating that the FMN site of complex I is the target of TAM
and/or E2 effects. Accordingly, Li and Trush (54) demonstrated that
diphenyleneiodonium, a DPI-related compound, inhibits superoxide
production in isolated mitochondria. Furthermore, Bailey et al. (55)
showed that incubation of untreated and ethanol-treated hepato-
cytes with rotenone significantly increased ROS levels, whereas pre-
treatment with DPI significantly attenuated ROS production. In the
same line, Caraceni et al. (56) reported similar effects of rotenone
and DPI on superoxide production induced in hepatocytes subjected
to anoxia reoxygenation injury.
Furthermore, to investigate whether an ER was involved in the regu-
lation of mitochondrial function by TAM and/or E2, we performed
some experiments using the pure ER antagonist, ICI. We observed that
ICI did not interfere with mitochondrial function (Figs. 3–10) and gen-
eration of ROS (Table 1). This finding is supported by previous studies
reporting the existence of ER-independent actions of estradiol (57) and
TAM (34).
In conclusion, our results demonstrate that TAMand/or E2 lead(s) to
mitochondrial failure by acting through the FMN site of mitochondrial
complex I (Fig. 11). This is an important aspect concerning cancer ther-
apy because mitochondrial failure may contribute to arrest disease pro-
gression. Furthermore, our study provides amechanistic basis to under-
stand the multiple cytotoxic effects of TAM and why TAM-resistant
breast cancer can revert to TAM-sensitive with the use of E2 at the right
time, as previously reported by Osipo et al. (15). Although we used liver
mitochondria as experimental model, we believe that our results can be
extrapolated to breast cancer cells for several reasons: 1) TAM is exten-
sively metabolized in the liver to give 4-hydroxytamoxifen and N-des-
methyltamoxifen (58); 2) the metabolism of estrogens mainly occurs in
liver (59); 3) mitochondria control steroidogenesis (60); and 4) mito-
chondria is an evolutionary conserved organelle. Altogether these data
open a new and promising therapeutic window aimed at fighting tumor
cell growth.
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